Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 27, Number 11—November 2021
Dispatch

Bordetella hinzii Pneumonia and Bacteremia in a Patient with SARS-CoV-2 Infection

Michele Maison-Fomotar and Geetha SivasubramanianComments to Author 
Author affiliation: University of California, San Francisco, Fresno, California, USA

Main Article

Table 1

Antimicrobial susceptibility of Bordetella hinzii isolate by broth dilution

Drug MIC* Interpretation
Amikacin 8 μg/mL Sensitive
Aztreonam ≥64 μg/mL Resistant
Cefepime ≥64 μg/mL Resistant
Ceftazidime ≥32 μg/mL Resistant
Ciprofloxacin ≥8 µg/ml Resistant
Gentamicin 4 μg/mL Sensitive
Levofloxacin 2 μg/mL Sensitive
Meropenem 2 μg/mL Sensitive
Piperacillin/tazobactam ≥128/4 μg/mL Resistant
Ticarcillin/clavulanic acid ≥256/2 μg/mL Resistant
Tobramycin 16 μg/mL Resistant

*MIC breakpoints were interpreted using CLSI guidelines (https://clsi.org).

Main Article

Page created: August 05, 2021
Page updated: October 19, 2021
Page reviewed: October 19, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external